WO2021038726A1 - 治療支援装置、治療光制御方法 - Google Patents

治療支援装置、治療光制御方法 Download PDF

Info

Publication number
WO2021038726A1
WO2021038726A1 PCT/JP2019/033560 JP2019033560W WO2021038726A1 WO 2021038726 A1 WO2021038726 A1 WO 2021038726A1 JP 2019033560 W JP2019033560 W JP 2019033560W WO 2021038726 A1 WO2021038726 A1 WO 2021038726A1
Authority
WO
WIPO (PCT)
Prior art keywords
light
treatment
intensity
fluorescence
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2019/033560
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
紘之 妻鳥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shimadzu Corp
Original Assignee
Shimadzu Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shimadzu Corp filed Critical Shimadzu Corp
Priority to PCT/JP2019/033560 priority Critical patent/WO2021038726A1/ja
Priority to EP19943649.4A priority patent/EP4023287A4/en
Priority to US17/637,872 priority patent/US20220288411A1/en
Priority to CN201980099753.3A priority patent/CN114286709B/zh
Priority to JP2021541846A priority patent/JP7435611B2/ja
Publication of WO2021038726A1 publication Critical patent/WO2021038726A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B2017/00017—Electrical control of surgical instruments
    • A61B2017/00022—Sensing or detecting at the treatment site
    • A61B2017/00057—Light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636—Sensing and controlling the application of energy
    • A61B2018/00773—Sensed parameters
    • A61B2018/00779—Power or energy
    • A61B2018/00785—Reflected power
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0626—Monitoring, verifying, controlling systems and methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0626—Monitoring, verifying, controlling systems and methods
    • A61N2005/0627—Dose monitoring systems and methods
    • A61N2005/0628—Dose monitoring systems and methods including a radiation sensor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0632—Constructional aspects of the apparatus
    • A61N2005/0633—Arrangements for lifting or hinging the frame which supports the light sources
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A61N2005/0663—Coloured light

Definitions

  • the present invention relates to a treatment support device and a treatment light control method.
  • a therapeutic agent in which an antibody of a fluorescent reagent (IR700) and an epidermal growth factor receptor (EGFR) is bound is injected into a subject.
  • IR700 fluorescent reagent
  • EGFR epidermal growth factor receptor
  • the irradiation time of the treatment light is determined in advance based on the treatment site and the light intensity of the treatment light, and the treatment site is irradiated with the treatment light of this irradiation time.
  • the therapeutic effect (that is, the progress of treatment) may differ depending on the subject, and when the treatment light is irradiated for a predetermined time, the treatment has already been completed. Regardless, the treatment light may be continuously irradiated, which increases the burden on the subject. On the other hand, the irradiation of the treatment light may be stopped even though the treatment has not been completed, and in this case, a problem that retreatment is required occurs.
  • the present invention has been made in view of such circumstances, and an object of the present invention is a treatment support device capable of appropriately controlling the treatment light according to a treatment effect (that is, the progress of treatment). It is to provide a therapeutic light control method.
  • the first aspect of the present invention is a treatment support in which the treatment light emitted toward the treatment site of a subject to which a therapeutic agent containing a fluorescent dye is administered is controlled, and the fluorescent dye is excited by the treatment light for treatment.
  • the device is a light source that emits therapeutic light, a control unit that controls the irradiation time and irradiation intensity of the therapeutic light, and detection that detects the intensity of fluorescence generated from the fluorescent dye when the therapeutic light is irradiated.
  • the control unit relates to a treatment support device that controls at least one of the irradiation time and the irradiation intensity of the treatment light based on the intensity of fluorescence.
  • a second aspect of the present invention is a therapeutic light in which the therapeutic light emitted toward the treatment site of a subject to which a therapeutic agent containing a fluorescent dye is administered is controlled, and the fluorescent dye is excited by the therapeutic light for treatment.
  • the control method is a step of emitting therapeutic light, a step of controlling the irradiation time and irradiation intensity of the therapeutic light, and a step of detecting the intensity of fluorescence generated from the fluorescent dye when the therapeutic light is being irradiated.
  • the step of controlling the therapeutic light including, relates to a therapeutic light control method for controlling at least one of the irradiation time and the irradiation intensity of the therapeutic light based on the intensity of fluorescence.
  • a treatment support device and a treatment light control method capable of appropriately controlling the treatment light according to the treatment effect (that is, the progress of the treatment) are realized.
  • FIG. 1 is a perspective view showing an embodiment of the treatment support device of the present invention.
  • FIG. 2 is a side view of the treatment support device shown in FIG.
  • FIG. 3 is a plan view of the treatment support device shown in FIG.
  • FIG. 4 is a block diagram showing a main control system of the treatment support device shown in FIG.
  • FIG. 5 is a flowchart of a treatment light control program executed by the treatment support device shown in FIG.
  • FIG. 6 is an example of an image displayed on the image display unit included in the treatment support device shown in FIG.
  • FIG. 7 is a graph showing the relationship between the treatment light irradiation time t and the fluorescence intensity P of the treatment support device shown in FIG.
  • FIG. 8 is a flowchart of the treatment light control program according to the first modification of the present invention.
  • FIG. 1 is a perspective view showing an embodiment of the treatment support device of the present invention.
  • FIG. 2 is a side view of the treatment support device shown in FIG.
  • FIG. 3 is a plan view of the treatment support device shown in FIG.
  • FIG. 4 is a block diagram showing a main control system of the treatment support device shown in FIG.
  • FIG. 5 is a flowchart of a treatment light control program executed by the treatment support device shown in FIG.
  • FIG. 6 is an example of an image displayed on the image display unit included in the treatment support device shown in FIG.
  • the upper side in FIGS. 1, 2 and 6 is referred to as “upper (upper)" and the lower side is referred to as "lower (lower)".
  • the treatment support device 1 shown in FIG. 1 is excited by light for a therapeutic agent (RM-1929) in which an antibody of a fluorescent reagent (IR700) injected into the body of a subject ST and an antibody of epidermal growth factor receptor (EGFR) is bound. It is a device for irradiating (hereinafter, also referred to as “therapeutic light”) and photographing the fluorescence emitted from this fluorescent reagent (IR700).
  • therapeutic light a device for irradiating
  • IR700 epidermal growth factor receptor
  • the treatment support device 1 includes a carriage 11 having four wheels 13 and an arm mechanism 30 arranged on the upper surface of the carriage 11 near the front of the carriage 11 in the traveling direction (leftward in FIGS. 2 and 3).
  • the arm mechanism 30 is provided with an illumination / photographing unit 12 arranged via a sub-arm 41 and an image display unit 15 as a monitor.
  • a handle 14 used when moving the carriage 11 is attached to the rear of the carriage 11 in the traveling direction.
  • a recess 16 for mounting a remote controller for remotely controlling the treatment support device 1 is formed on the upper surface of the carriage 11.
  • the treatment light control program is executed (that is, each step shown in FIG. 5 is executed), and the visible image IM1 is displayed on the image display unit 15.
  • the fluorescence image IM2 and the composite image IM3 are displayed, and the irradiation time and irradiation intensity of the treatment light are controlled (FIG. 6).
  • the arm mechanism 30 described above is arranged on the front side of the carriage 11 in the traveling direction.
  • the arm mechanism 30 includes a first arm member 31 connected by a hinge portion 33 to a support portion 37 arranged on a support column 36 erected on the front side in the traveling direction of the carriage 11.
  • the first arm member 31 can swing with respect to the carriage 11 via the support column 36 and the support portion 37 by the action of the hinge portion 33.
  • the image display unit 15 described above is attached to the support column 36.
  • a second arm member 32 is connected to the upper end of the first arm member 31 by a hinge portion 34.
  • the second arm member 32 can swing with respect to the first arm member 31 by the action of the hinge portion 34. Therefore, as shown by the virtual line with the symbol C in FIG. 2, the first arm member 31 and the second arm member 32 are the first arm member 31 and the second arm member 32 is the first arm member 31.
  • the first arm member 31 and the first arm member 31 as shown by a shooting posture opened at a predetermined angle about the hinge portion 34 which is a connecting portion between the second arm member 32 and the second arm member 32 and a solid line with a sign A in FIGS. 1 to 3. It is possible to take a standby posture in which the second arm member 32 is in close proximity.
  • a support portion 43 is connected to the lower end of the second arm member 32 by a hinge portion 35.
  • the support portion 43 can swing with respect to the second arm member 32 by the action of the hinge portion 35.
  • a rotating shaft 42 is supported by the support portion 43.
  • the sub-arm 41 that supports the illumination / photographing unit 12 rotates about a rotation shaft 42 arranged at the tip of the second arm member 32. Therefore, the illumination / photographing unit 12 shoots by rotating the sub-arm 41 as shown by the solid line with the sign A in FIGS. 1 to 3 or the virtual line with the sign C in FIG.
  • the illumination / photographing unit 12 includes a light source unit 24, a light source control unit 25, a zoom lens 26, a prism 27, a white light sensor 28, and an excitation light sensor 29.
  • the lighting / photographing unit 12 is separated from the affected area of the subject ST by about several tens of cm.
  • the light source unit 24 includes a first light source 241 which is a white light source and a second light source 242 which is an excitation light source.
  • a first light source 241 which is a white light source
  • a second light source 242 which is an excitation light source.
  • the second light source 242 irradiates the excitation light (therapeutic light) for exciting the fluorescent reagent (IR700).
  • excitation light near-infrared light
  • RM-1929 the fluorescence of the reagent administered to the subject ST
  • the reagent (IR700) is excited.
  • the fluorescent reagent (IR700) near-infrared light having a peak of about 700 nm is emitted as fluorescence and detected by the excitation light sensor 29.
  • the light source control unit 25 has a function of controlling the lighting of the first light source 241. With this function, the first light source 241 can be irradiated with white light and stopped thereof. Further, the light source control unit 25 has a function of controlling the lighting of the second light source 242 and a function of controlling the amount of light of the second light source 242. By these functions, the irradiation time and the irradiation intensity of the therapeutic light emitted from the second light source 242 are controlled.
  • the light source control unit 25 is connected to a control unit 17 that controls the treatment support device 1 as a whole, and the first light source 241 and the second light source 242 are controlled according to instructions from the control unit 17.
  • the reflected light (white light) reflected by the subject ST and the fluorescence generated by the fluorescent reagent (IR700) in the subject ST are incident on the zoom lens 26. Then, by the zoom lens 26, the reflected light (white light) is imaged on the white light sensor 28, and the fluorescence is imaged on the excitation light sensor 29.
  • Light from the zoom lens 26, that is, white light and fluorescence is incident on the prism 27, but the white light and fluorescence incident on the prism 27 are separated by the prism 27, and the white light is directed to the white light sensor 28.
  • the fluorescence is configured to direct the excitation light sensor 29.
  • the white light sensor 28 is an image sensor that detects a part of the reflected light (white light) separated by the prism 27.
  • the frame rate of NTSC National Television System Committee
  • the excitation light sensor 29 is an image pickup device that detects a part of near-infrared light (fluorescence) separated by a prism 27, and has an NTSC frame rate (for example, 30 frames / second (60 fields / second)).
  • the fluorescence image of the subject ST is imaged in.
  • the treatment support device 1 includes a control unit 17, an image forming unit 18, an image synthesizing unit 19, a storage unit 20, and an operation unit 10. Each of these parts is arranged on the carriage 11.
  • the control unit 17 is composed of a CPU that executes logical operations, a ROM that stores an operation program necessary for controlling the device, a RAM that temporarily stores data and the like during control, and has a function of controlling the entire device. I have.
  • the control unit 17 is electrically connected to the light source control unit 25, the image forming unit 18, the image synthesizing unit 19, the image display unit 15, the storage unit 20, and the operation unit 10, and the power is input to the treatment support device 1. Then, the treatment light control program stored in the storage unit 20 is read out, and each of these units is controlled.
  • the image forming unit 18 includes a first imaging unit 181 that acquires a visible image IM1 by photographing the subject ST irradiated with white light at a frame rate of NTSC, and a fluorescent reagent ( By photographing the fluorescence generated in IR700) at the frame rate of NTSC, it functions as a second photographing unit 182 for acquiring the fluorescence image IM2.
  • the image synthesizing unit 19 synthesizes (generates) the composite image IM3 by synthesizing the visible image IM1 formed by the image forming unit 18 and the fluorescence image IM2. As shown in FIG. 6, in the present embodiment, the visible image IM1, the fluorescence image IM2, and the composite image IM3 are collectively displayed on the image display unit 15. Then, by observing the composite image IM3, the doctor can accurately grasp the treatment position and the treatment effect (that is, the progress of the treatment) of the subject ST.
  • the storage unit 20 is configured to store the treatment light control program executed by the control unit 17, the brightness value of the fluorescence image IM2 formed by the image forming unit 18, and the like.
  • the operation unit 10 is a user interface for operating the treatment support device 1.
  • the operation unit 10 is configured to be able to set irradiation of light from the light source unit 24, stop of irradiation, adjustment of brightness and sensitivity, display method of an image displayed on the image display unit 15, and the like.
  • the treatment optical control program is a process that is read from the storage unit 20 and executed by the control unit 17 when the power is input to the treatment support device 1.
  • step S101 when the therapeutic light control program is executed, the control unit 17 controls the light source control unit 25 and turns on the first light source 241.
  • the first light source 241 When the first light source 241 is turned on, white light is emitted toward the subject ST.
  • step S101 the process proceeds to step S103.
  • step S103 the control unit 17 controls the first photographing unit 181 of the image forming unit 18 and acquires the visible image IM1 from the data of the white light sensor 28 input to the image forming unit 18 at the NTSC frame rate. ..
  • step S105 the process proceeds to step S105.
  • step S105 the control unit 17 controls the image composition unit 19 and the image display unit 15, sends the visible image IM1 acquired in step S103 to the image composition unit 19, and displays the visible image IM1 on the image display unit 15. .
  • the process of step S105 proceeds to step S107.
  • step S107 the control unit 17 determines whether or not the treatment light switch (switch for irradiating the treatment light) of the operation unit 10 is turned on. Then, when the treatment light switch is turned on (step S107: YES), the process proceeds to step S109, and when the excitation light switch is turned off (step S107: NO), the process proceeds to step S115. ..
  • step S109 the control unit 17 controls the light source control unit 25 and turns on the second light source 242.
  • the second light source 242 is turned on, the therapeutic light is emitted toward the subject ST.
  • step S109 the process proceeds to step S111.
  • step S111 the control unit 17 controls the second imaging unit 182 of the image forming unit 18 and acquires the fluorescence image IM2 from the data of the excitation light sensor 29 input to the image forming unit 18 at the NTSC frame rate. .. More specifically, in the present embodiment, one frame of the fluorescence image IM2 is acquired and stored in the storage unit 20.
  • step S111 the process proceeds to step S113.
  • step S113 the control unit 17 controls the image synthesis unit 19 and the image display unit 15, and sends the fluorescence image IM2 acquired and saved in step S111 to the image composition unit 19, and also sends the fluorescence image IM2 to the image display unit 15. Is displayed.
  • step S113 the process proceeds to step S114.
  • step S114 the control unit 17 obtains the fluorescence irradiation intensity (hereinafter referred to as “fluorescence intensity P”) from the fluorescence image IM2 acquired and stored in step S111, and stores (stores) it in the storage unit 20. More specifically, in the present embodiment, the control unit 17 identifies a pixel that is receiving fluorescence in the fluorescence image IM2, and obtains a fluorescence intensity P (mW) based on the average luminance value of the pixel. It is stored in the storage unit 20.
  • FIG. 7 is a graph showing the relationship between the treatment light irradiation time t and the fluorescence intensity P. As shown in FIG.
  • step S109 when the therapeutic light is irradiated toward the subject ST in step S109, fluorescence derived from the fluorescent reagent (IR700) in the subject ST is detected, but with the passage of time ( That is, as the therapeutic light irradiation time t becomes longer), the reaction of the fluorescent reagent (IR700) proceeds, so that the fluorescence intensity P gradually decreases.
  • the fluorescence intensity P becomes smaller than the predetermined threshold value Pth, the amount of change in the fluorescence intensity P becomes extremely small. Therefore, in the present embodiment, when the fluorescence intensity P becomes equal to or less than a predetermined threshold value Pth (at the time ts in FIG. 7), it is determined that the treatment is completed (step S119), and step S114. Then, the fluorescence intensity P of each fluorescence image IM2 is obtained prior to step S119.
  • the process of step S114 is completed, the process proceeds to step S115.
  • step S115 the control unit 17 controls the image composition unit 19 and superimposes and synthesizes the visible image IM1 acquired in step S103 and the fluorescence image IM2 acquired in step S111 to generate the composite image IM3.
  • the process of step S115 proceeds to step S117.
  • step S117 the control unit 17 controls the image display unit 15 and displays the composite image IM3 generated in step S115 on the image display unit 15.
  • step S119 the process proceeds to step S119.
  • step S119 the control unit 17 determines whether or not the fluorescence intensity P stored in the storage unit 20 in step S114 is equal to or less than a predetermined threshold value Pth. Then, when the fluorescence intensity P becomes equal to or less than the predetermined threshold value Pth, the control unit 17 determines that the treatment is completed and ends the treatment light control program (step S119: YES), and the fluorescence intensity P is predetermined. If the threshold value is not less than or equal to Pth (step S119: NO), the process returns to step S103, and steps S103 to S119 are repeated.
  • the doctor observes the composite image IM3 to perform the subject ST. It is possible to accurately grasp the treatment position and treatment effect (that is, the progress of treatment). Further, in the present embodiment, the fluorescence intensity P of each fluorescence image IM2 is obtained in step S114, and in step S119 it is determined whether or not the fluorescence intensity P is equal to or less than a predetermined threshold value Pth, and the fluorescence intensity P is determined.
  • the treatment light control program is terminated (that is, the irradiation of the treatment light is stopped), which is unnecessary for the subject ST. No treatment light is applied. That is, the therapeutic light is appropriately controlled according to the therapeutic effect (that is, the progress of the treatment).
  • the fluorescence intensity P is obtained based on the average luminance value of the pixels receiving fluorescence in the fluorescence image IM2, but the configuration is limited to such a configuration.
  • the fluorescence intensity P can be obtained based on the maximum luminance value in the fluorescence image IM2.
  • step S119: NO when the fluorescence intensity P is not equal to or less than the predetermined threshold value Pth (step S119: NO), steps S103 to S119 are repeated, and the fluorescence intensity P is predetermined.
  • the configuration is such that the treatment light is irradiated until the threshold value becomes Pth or less (that is, the configuration is such that the irradiation time of the treatment light is controlled), but the configuration is not limited to this configuration.
  • the fluorescence intensity P is not equal to or less than a predetermined threshold value Pth (step S119: NO)
  • the irradiation intensity of the therapeutic light may be increased.
  • the reaction of the fluorescent reagent (IR700) proceeds, so that the irradiation time of the treatment light (that is, the treatment time) can be shortened.
  • the irradiation time and the irradiation intensity of the therapeutic light may be controlled.
  • FIG. 8 is a flowchart of a treatment light control program shown as a modification 1 of the present embodiment.
  • the control unit 17 stores the fluorescence intensity P (n) in the storage unit 20 in step S114 and the storage unit 20 in step S114 one frame before.
  • the configuration differs from that of the present embodiment in that the amount of change ⁇ P is obtained from the difference in the stored fluorescence intensity P (n-1) , and it is determined whether or not the amount of change ⁇ P is equal to or less than a predetermined threshold value ⁇ Pth.
  • step S119A YES
  • step S119A NO
  • the treatment light control program is terminated (that is, the irradiation of the treatment light is stopped). Therefore, the subject ST is not irradiated with unnecessary therapeutic light. That is, the therapeutic light is appropriately controlled according to the therapeutic effect (that is, the progress of the treatment).
  • the treatment support device is A treatment support device that controls the treatment light emitted toward the treatment site of a subject to whom a therapeutic agent containing a fluorescent dye is administered, and excites the fluorescent dye with the treatment light for treatment.
  • the light source that emits the therapeutic light
  • a control unit that controls the irradiation time and irradiation intensity of the treatment light
  • a detection unit that detects the intensity of fluorescence generated from the fluorescent dye when the treatment light is irradiated.
  • the control unit controls at least one of the irradiation time and the irradiation intensity of the therapeutic light based on the intensity of the fluorescence.
  • the treatment light is appropriately controlled according to the treatment effect (that is, the progress of the treatment), so that the subject is irradiated with unnecessary treatment light. Will not be done.
  • the control unit controls at least one of the irradiation time and the irradiation intensity of the treatment light so that the fluorescence intensity is equal to or less than a predetermined threshold value.
  • the treatment light is controlled so that the fluorescence intensity is equal to or less than a predetermined threshold value, so that unnecessary irradiation of the treatment light to the subject is surely prevented. Will be done.
  • the control unit calculates the amount of change in the fluorescence intensity per predetermined time based on the fluorescence intensity stored in the storage unit, and makes the change amount equal to or less than a predetermined threshold value. At least one of the irradiation time and the irradiation intensity of the treatment light is controlled.
  • the treatment light is controlled so that the amount of change in fluorescence intensity is equal to or less than a predetermined threshold value, so that the subject is irradiated with unnecessary treatment light. It is definitely prevented.
  • An imaging unit that acquires a fluorescence image by imaging the fluorescence generated from the fluorescent dye when the treatment light is irradiated is further provided.
  • the detection unit detects the intensity of the fluorescence based on the brightness value of the fluorescence image.
  • the fluorescence intensity can be easily detected from the brightness value of the fluorescence image.
  • the therapeutic light is light having a wavelength of 600 to 750 nm.
  • the fluorescent dye can be reliably excited.
  • the therapeutic light control method is A therapeutic light control method in which a therapeutic light emitted toward a treatment site of a subject to which a therapeutic agent containing a fluorescent dye is administered is controlled, and the fluorescent dye is excited by the therapeutic light for treatment.
  • the step of controlling the therapeutic light controls at least one of the irradiation time and the irradiation intensity of the therapeutic light based on the intensity of the fluorescence.
  • the treatment light is appropriately controlled according to the treatment effect (that is, the progress of the treatment), so that unnecessary treatment light is emitted to the subject. Not irradiated.
  • the step of controlling the therapeutic light controls at least one of the irradiation time and the irradiation intensity of the therapeutic light so that the fluorescence intensity is equal to or less than a predetermined threshold value.
  • the treatment light is controlled so that the fluorescence intensity is equal to or less than a predetermined threshold value, so that the subject is surely irradiated with unnecessary treatment light. Be prevented.
  • the amount of change in the fluorescence intensity per predetermined time is calculated based on the stored fluorescence intensity, and the amount of change is equal to or less than a predetermined threshold value. At least one of the irradiation time and the irradiation intensity of the treatment light is controlled.
  • the therapeutic light is controlled so that the amount of change in fluorescence intensity is equal to or less than a predetermined threshold value, so that the subject is irradiated with unnecessary therapeutic light. Is definitely prevented.
  • the fluorescence intensity can be easily detected from the brightness value of the fluorescence image.
  • the therapeutic light is light having a wavelength of 600 to 750 nm.
  • the fluorescent dye can be reliably excited.
  • Treatment support device 2 Treatment support device 10: Operation unit 11: Cart 12: Imaging unit 13: Wheel 14: Handle 15: Image display unit 16: Recess 17: Control unit 18: Image forming unit 19: Image composition unit 20 : Storage unit 24: Light source unit 25: Light source control unit 26: Zoom lens 27: Prism 28: White light sensor 29: Excitation light sensor 30: Arm mechanism 31: First arm member 32: Second arm member 33: Hinge unit 34 : Hinge part 35: Hinge part 36: Support 37: Support part 41: Sub-arm 42: Rotating shaft 43: Support part 181: First photographing part 182: Second photographing part 241: First light source 242: Second Light source IM1: Visible image IM2: Fluorescent image IM3: Composite image ST: Subject

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Radiation-Therapy Devices (AREA)
PCT/JP2019/033560 2019-08-27 2019-08-27 治療支援装置、治療光制御方法 Ceased WO2021038726A1 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
PCT/JP2019/033560 WO2021038726A1 (ja) 2019-08-27 2019-08-27 治療支援装置、治療光制御方法
EP19943649.4A EP4023287A4 (en) 2019-08-27 2019-08-27 TREATMENT ASSISTANT DEVICE AND METHOD OF CONTROLLING THERAPY LIGHT
US17/637,872 US20220288411A1 (en) 2019-08-27 2019-08-27 Treatment support device and therapeutic light control method
CN201980099753.3A CN114286709B (zh) 2019-08-27 2019-08-27 治疗辅助装置、治疗光控制方法
JP2021541846A JP7435611B2 (ja) 2019-08-27 2019-08-27 治療支援装置、治療光制御方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2019/033560 WO2021038726A1 (ja) 2019-08-27 2019-08-27 治療支援装置、治療光制御方法

Publications (1)

Publication Number Publication Date
WO2021038726A1 true WO2021038726A1 (ja) 2021-03-04

Family

ID=74684710

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/033560 Ceased WO2021038726A1 (ja) 2019-08-27 2019-08-27 治療支援装置、治療光制御方法

Country Status (5)

Country Link
US (1) US20220288411A1 (https=)
EP (1) EP4023287A4 (https=)
JP (1) JP7435611B2 (https=)
CN (1) CN114286709B (https=)
WO (1) WO2021038726A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023112089A1 (ja) * 2021-12-13 2023-06-22 株式会社島津製作所 治療支援装置

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102020117579A1 (de) * 2020-07-03 2022-01-05 Hoya Corporation Endoskopisches Beleuchtungssystem für ein Fluoreszenzmittel
WO2022061366A1 (en) * 2020-09-18 2022-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Monitoring of autonomic nervous system activity through sweat pore activation
JP7476755B2 (ja) * 2020-10-19 2024-05-01 株式会社島津製作所 治療支援装置

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014221117A (ja) * 2013-05-13 2014-11-27 株式会社アライ・メッドフォトン研究所 治療進行度モニタ装置及びその方法
WO2016151888A1 (ja) * 2015-03-26 2016-09-29 オリンパス株式会社 画像処理装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101677751B (zh) * 2007-05-22 2012-06-27 奥林巴斯株式会社 胶囊型医疗装置和胶囊型医疗系统
JP2009112804A (ja) * 2007-10-18 2009-05-28 Minato Ikagaku Kk Ｉｇｆ−１の体内産生を促進する青色光刺激装置及びその方法
JP2011167344A (ja) * 2010-02-18 2011-09-01 Fujifilm Corp Ｐｄｔ用医療装置システム、電子内視鏡システム、手術用顕微鏡システム、及び治療光照射分布制御方法
JP5719159B2 (ja) * 2010-03-15 2015-05-13 ソニー株式会社 評価装置
CN103153155B (zh) * 2011-03-15 2014-09-10 奥林巴斯医疗株式会社 医疗装置
CN103608662B (zh) * 2011-06-29 2016-09-28 京都府公立大学法人 肿瘤部位的识别装置以及识别方法
CA2841120C (en) 2011-07-11 2020-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-ir700 conjugates for photodynamic therapy
JP6432533B2 (ja) * 2016-01-14 2018-12-05 株式会社島津製作所 イメージング装置
JP6897483B2 (ja) 2017-10-18 2021-06-30 株式会社ニコン 光照射装置、光照射プログラム、及び光照射装置の駆動方法
KR101903423B1 (ko) * 2018-02-20 2018-10-04 한국광기술원 광진단 및 광치료를 위한 하이브리드 이미징 시스템
JP2019048111A (ja) * 2018-11-07 2019-03-28 株式会社島津製作所 イメージング方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014221117A (ja) * 2013-05-13 2014-11-27 株式会社アライ・メッドフォトン研究所 治療進行度モニタ装置及びその方法
WO2016151888A1 (ja) * 2015-03-26 2016-09-29 オリンパス株式会社 画像処理装置

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
K. SATO ET AL.: "Photo-induced ligand release from a silicon phthalocyanine dye conjugated with monoclonal antibodies; A mechanism of cancer cell cytotoxicity after near infrared photoimmunotherapy", ACS CENTRAL SCIENCE, 7 November 2018 (2018-11-07)
See also references of EP4023287A4
SHIMADZU CORP., FIRST SUCCESS IN DEVELOPING OPTICAL REMOTE CONTROLLER SWITCHES THAT KILL ONLY TARGET CELLS - EXPECTED TO CONTRIBUTE TO CANCER TREATMENT WITH LESS SIDE EFFECTS, 10 March 2019 (2019-03-10), Retrieved from the Internet <URL:https://WWW.SHIMADZU.CO.JP/news/press/9qbnqudlmddlrfby.html>>

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023112089A1 (ja) * 2021-12-13 2023-06-22 株式会社島津製作所 治療支援装置
JPWO2023112089A1 (https=) * 2021-12-13 2023-06-22
JP7819703B2 (ja) 2021-12-13 2026-02-25 株式会社島津製作所 治療支援装置

Also Published As

Publication number Publication date
EP4023287A4 (en) 2023-05-17
CN114286709B (zh) 2025-06-03
US20220288411A1 (en) 2022-09-15
CN114286709A (zh) 2022-04-05
JPWO2021038726A1 (https=) 2021-03-04
JP7435611B2 (ja) 2024-02-21
EP4023287A1 (en) 2022-07-06

Similar Documents

Publication Publication Date Title
WO2021038726A1 (ja) 治療支援装置、治療光制御方法
JP2024038065A (ja) イメージング方法
JP6721644B2 (ja) 蛍光ベースのレーザーアブレーションのためのシステム及び方法
JP6129462B1 (ja) 内視鏡システム
JP5117801B2 (ja) 眼底撮影装置
CN112153942A (zh) 治疗辅助装置
CN105615823B (zh) 眼科设备和眼科设备的控制方法
US6932762B2 (en) Endoscope having red component cut filter
JP7486331B2 (ja) 制御装置および医療用観察システム
JP2023172891A (ja) 内視鏡システム
JP7200755B2 (ja) イメージング装置およびイメージング装置の作動方法
JP7521584B2 (ja) 治療支援システム
JP2009022500A (ja) 眼底撮影装置
US20250009215A1 (en) Image processing device, phototherapy system, image processing method, computer-readable recording medium, and phototherapy method
US20230076477A1 (en) Imaging device and imaging method
CN117838020A (zh) 内窥镜系统以及光治疗方法
US20200022580A1 (en) Imaging device
JP2018124664A (ja) 画像処理装置およびイメージング装置
JP2020202955A (ja) イメージング装置
JP2018195247A (ja) 画像処理装置およびイメージング装置

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19943649

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021541846

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019943649

Country of ref document: EP

Effective date: 20220328

WWW Wipo information: withdrawn in national office

Ref document number: 2019943649

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 201980099753.3

Country of ref document: CN